94 related articles for article (PubMed ID: 23894722)
1. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR
Ming Lim C; Stephenson R; Salazar AM; Ferris RL
Oncoimmunology; 2013 Jun; 2(6):e24677. PubMed ID: 23894722
[TBL] [Abstract][Full Text] [Related]
2. A peptide inhibitor of antibody-dependent cell-mediated cytotoxicity against EGFR/folate receptor-α double positive cells.
Sasaki K; Miyashita Y; Asai D; Funamoto D; Sato K; Yamaguchi Y; Mishima Y; Iino T; Takaishi S; Nagano J; Kishimura A; Mori T; Katayama Y
Medchemcomm; 2018 May; 9(5):783-788. PubMed ID: 30108967
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic switching as a non-genetic mechanism of resistance predicts antibody therapy regimens.
Zhou J; Liu C; Tang Y; Li Z; Cao Y
iScience; 2024 Apr; 27(4):109450. PubMed ID: 38544569
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological problems of the local tissue effect of the copper-releasing intrauterine contraceptive device (IUD). I. General characteristics of the copper-containing IUD (clinical study).
Patai K; Balogh I; Szarvas Z
Acta Chir Hung; 1989; 30(2):129-32. PubMed ID: 2669431
[TBL] [Abstract][Full Text] [Related]
5. PLODs: Novel prognostic biomarkers and potential immunotherapy targets for head and neck squamous cell carcinoma.
Gong S; Wu C; Duan Y; Fu J; Wang Y; Wu H; Zhang B; Tang J; Wu P
Heliyon; 2023 Feb; 9(2):e13479. PubMed ID: 36820030
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes.
Ge H; Ferris RL; Wang JH
Clin Cancer Res; 2023 Feb; 29(3):647-658. PubMed ID: 36315045
[TBL] [Abstract][Full Text] [Related]
7. Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics.
Olmeda D; Cerezo-Wallis D; Mucientes C; Calvo TG; Cañón E; Alonso-Curbelo D; Ibarz N; Muñoz J; Rodriguez-Peralto JL; Ortiz-Romero P; Ortega S; Soengas MS
EMBO Mol Med; 2021 Dec; 13(12):e12924. PubMed ID: 34762341
[TBL] [Abstract][Full Text] [Related]
8. NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models.
Gruijs M; Ganzevles SH; Stigter-van Walsum M; van der Mast R; van Ostaijen-Ten Dam MM; Tuk CW; Schilham MW; Leemans CR; Brakenhoff RH; van Egmond M; van de Ven R; Bakema JE
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681717
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating CD8
Kumar S; Singh SK; Rana B; Rana A
Drug Discov Today; 2021 Apr; 26(4):951-967. PubMed ID: 33450394
[TBL] [Abstract][Full Text] [Related]
10. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
11. Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function.
Gao R; Sheng Z; Sreenivasan CC; Wang D; Li F
Viruses; 2020 Mar; 12(3):. PubMed ID: 32121563
[TBL] [Abstract][Full Text] [Related]
12. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
[TBL] [Abstract][Full Text] [Related]
13. The TLR3 Agonist Poly Inosinic:Cytidylic Acid Significantly Augments the Therapeutic Activity of an Anti-CD7 Immunotoxin for Human T-cell Leukaemia.
Flavell DJ; Holmes SE; Warnes SL; Flavell SU
Biomedicines; 2019 Feb; 7(1):. PubMed ID: 30781517
[TBL] [Abstract][Full Text] [Related]
14. Enhancing the immune stimulatory effects of cetuximab therapy through TLR3 signalling in Epstein-Barr virus (EBV) positive nasopharyngeal carcinoma.
Tan LSY; Wong B; Gangodu NR; Lee AZE; Kian Fong Liou A; Loh KS; Li H; Yann Lim M; Salazar AM; Lim CM
Oncoimmunology; 2018; 7(11):e1500109. PubMed ID: 30377565
[TBL] [Abstract][Full Text] [Related]
15. T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response.
Kansy BA; Shayan G; Jie HB; Gibson SP; Lei YL; Brandau S; Lang S; Schmitt NC; Ding F; Lin Y; Ferris RL
Oncoimmunology; 2018; 7(11):e1494112. PubMed ID: 30377562
[TBL] [Abstract][Full Text] [Related]
16. Stimulation of natural killer cells with rhCD137 ligand enhances tumor-targeting antibody efficacy in gastric cancer.
Misumi T; Tanabe K; Fujikuni N; Ohdan H
PLoS One; 2018; 13(10):e0204880. PubMed ID: 30321186
[TBL] [Abstract][Full Text] [Related]
17. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.
Ochoa MC; Minute L; Rodriguez I; Garasa S; Perez-Ruiz E; Inogés S; Melero I; Berraondo P
Immunol Cell Biol; 2017 Apr; 95(4):347-355. PubMed ID: 28138156
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment.
Rajasekaran N; Chester C; Yonezawa A; Zhao X; Kohrt HE
Immunotargets Ther; 2015; 4():91-100. PubMed ID: 27471715
[TBL] [Abstract][Full Text] [Related]
19. Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy.
Iribarren K; Bloy N; Buqué A; Cremer I; Eggermont A; Fridman WH; Fucikova J; Galon J; Špíšek R; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2016 Mar; 5(3):e1088631. PubMed ID: 27141345
[TBL] [Abstract][Full Text] [Related]
20. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Robert L; Ribas A; Hu-Lieskovan S
Semin Immunol; 2016 Feb; 28(1):73-80. PubMed ID: 26861544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
